Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Chari A, et al. Among authors: ifthikharuddin jj. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. Blood. 2017. PMID: 28637662 Free PMC article. Clinical Trial.
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL 2nd. Liesveld JL, et al. Among authors: ifthikharuddin jj. Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 Sep 8. Leuk Res. 2013. PMID: 24138944 Clinical Trial.
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Walker AR, et al. Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20. Leuk Res. 2008. PMID: 18571721 Clinical Trial.
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL 2nd, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. Phillips GL 2nd, et al. Among authors: ifthikharuddin jj. Biol Blood Marrow Transplant. 2011 Jul;17(7):1033-42. doi: 10.1016/j.bbmt.2010.11.003. Epub 2010 Nov 11. Biol Blood Marrow Transplant. 2011. PMID: 21074630 Free article. Clinical Trial.
A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.
Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ, Vescio R, Holmberg LA, Phillips GL. Bensinger WI, et al. Among authors: ifthikharuddin jj. Bone Marrow Transplant. 2016 Jan;51(1):67-71. doi: 10.1038/bmt.2015.211. Epub 2015 Sep 14. Bone Marrow Transplant. 2016. PMID: 26367217 Free PMC article. Clinical Trial.
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. Phillips GL, et al. Among authors: ifthikharuddin jj. Semin Oncol. 2004 Dec;31(6 Suppl 18):59-61. doi: 10.1053/j.seminoncol.2004.12.014. Semin Oncol. 2004. PMID: 15726525 Clinical Trial.
18 results